Cargando…
IL-20 Activates ERK1/2 and Suppresses Splicing of X-Box Protein-1 in Intestinal Epithelial Cells but Does Not Improve Pathology in Acute or Chronic Models of Colitis
The cytokine Interleukin (IL)-20 belongs to the IL-10 superfamily. IL-20 levels are reported to increase in the intestines of Ulcerative Colitis (UC) patients, however not much is known about its effects on intestinal epithelial cells. Here, we investigated the influence of IL-20 on intestinal epith...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820550/ https://www.ncbi.nlm.nih.gov/pubmed/36613621 http://dx.doi.org/10.3390/ijms24010174 |
_version_ | 1784865491018317824 |
---|---|
author | Moniruzzaman, Md. Wong, Kuan Yau Wang, Ran Symon, Hamish Mueller, Alexandra Rahman, M. Arifur Hasnain, Sumaira Z. |
author_facet | Moniruzzaman, Md. Wong, Kuan Yau Wang, Ran Symon, Hamish Mueller, Alexandra Rahman, M. Arifur Hasnain, Sumaira Z. |
author_sort | Moniruzzaman, Md. |
collection | PubMed |
description | The cytokine Interleukin (IL)-20 belongs to the IL-10 superfamily. IL-20 levels are reported to increase in the intestines of Ulcerative Colitis (UC) patients, however not much is known about its effects on intestinal epithelial cells. Here, we investigated the influence of IL-20 on intestinal epithelial cell lines and primary intestinal organoid cultures. By using chemical-induced (dextran sodium sulphate; DSS) colitis and a spontaneous model of colitis (Winnie mice), we assess whether recombinant IL-20 treatment is beneficial in reducing/improving pathology. Following stimulation with IL-20, intestinal primary organoids from wild-type and Winnie mice increased the expression of ERK1/2. However, this was lost when cells were differentiated into secretory goblet cells. Importantly, IL-20 treatment significantly reduced endoplasmic reticulum (ER) stress, as measured by spliced-XBP1 in epithelial cells, and this effect was lost in the goblet cells. IL-20 treatment in vivo in the DSS and Winnie models had minimal effects on pathology, but a decrease in macrophage activation was noted. Taken together, these data suggest a possible, but subtle role of IL-20 on epithelial cells in vivo. The therapeutic potential of IL-20 could be harnessed by the development of a targeted therapy or combination therapy to improve the healing of the mucosal barrier. |
format | Online Article Text |
id | pubmed-9820550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98205502023-01-07 IL-20 Activates ERK1/2 and Suppresses Splicing of X-Box Protein-1 in Intestinal Epithelial Cells but Does Not Improve Pathology in Acute or Chronic Models of Colitis Moniruzzaman, Md. Wong, Kuan Yau Wang, Ran Symon, Hamish Mueller, Alexandra Rahman, M. Arifur Hasnain, Sumaira Z. Int J Mol Sci Article The cytokine Interleukin (IL)-20 belongs to the IL-10 superfamily. IL-20 levels are reported to increase in the intestines of Ulcerative Colitis (UC) patients, however not much is known about its effects on intestinal epithelial cells. Here, we investigated the influence of IL-20 on intestinal epithelial cell lines and primary intestinal organoid cultures. By using chemical-induced (dextran sodium sulphate; DSS) colitis and a spontaneous model of colitis (Winnie mice), we assess whether recombinant IL-20 treatment is beneficial in reducing/improving pathology. Following stimulation with IL-20, intestinal primary organoids from wild-type and Winnie mice increased the expression of ERK1/2. However, this was lost when cells were differentiated into secretory goblet cells. Importantly, IL-20 treatment significantly reduced endoplasmic reticulum (ER) stress, as measured by spliced-XBP1 in epithelial cells, and this effect was lost in the goblet cells. IL-20 treatment in vivo in the DSS and Winnie models had minimal effects on pathology, but a decrease in macrophage activation was noted. Taken together, these data suggest a possible, but subtle role of IL-20 on epithelial cells in vivo. The therapeutic potential of IL-20 could be harnessed by the development of a targeted therapy or combination therapy to improve the healing of the mucosal barrier. MDPI 2022-12-22 /pmc/articles/PMC9820550/ /pubmed/36613621 http://dx.doi.org/10.3390/ijms24010174 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Moniruzzaman, Md. Wong, Kuan Yau Wang, Ran Symon, Hamish Mueller, Alexandra Rahman, M. Arifur Hasnain, Sumaira Z. IL-20 Activates ERK1/2 and Suppresses Splicing of X-Box Protein-1 in Intestinal Epithelial Cells but Does Not Improve Pathology in Acute or Chronic Models of Colitis |
title | IL-20 Activates ERK1/2 and Suppresses Splicing of X-Box Protein-1 in Intestinal Epithelial Cells but Does Not Improve Pathology in Acute or Chronic Models of Colitis |
title_full | IL-20 Activates ERK1/2 and Suppresses Splicing of X-Box Protein-1 in Intestinal Epithelial Cells but Does Not Improve Pathology in Acute or Chronic Models of Colitis |
title_fullStr | IL-20 Activates ERK1/2 and Suppresses Splicing of X-Box Protein-1 in Intestinal Epithelial Cells but Does Not Improve Pathology in Acute or Chronic Models of Colitis |
title_full_unstemmed | IL-20 Activates ERK1/2 and Suppresses Splicing of X-Box Protein-1 in Intestinal Epithelial Cells but Does Not Improve Pathology in Acute or Chronic Models of Colitis |
title_short | IL-20 Activates ERK1/2 and Suppresses Splicing of X-Box Protein-1 in Intestinal Epithelial Cells but Does Not Improve Pathology in Acute or Chronic Models of Colitis |
title_sort | il-20 activates erk1/2 and suppresses splicing of x-box protein-1 in intestinal epithelial cells but does not improve pathology in acute or chronic models of colitis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820550/ https://www.ncbi.nlm.nih.gov/pubmed/36613621 http://dx.doi.org/10.3390/ijms24010174 |
work_keys_str_mv | AT moniruzzamanmd il20activateserk12andsuppressessplicingofxboxprotein1inintestinalepithelialcellsbutdoesnotimprovepathologyinacuteorchronicmodelsofcolitis AT wongkuanyau il20activateserk12andsuppressessplicingofxboxprotein1inintestinalepithelialcellsbutdoesnotimprovepathologyinacuteorchronicmodelsofcolitis AT wangran il20activateserk12andsuppressessplicingofxboxprotein1inintestinalepithelialcellsbutdoesnotimprovepathologyinacuteorchronicmodelsofcolitis AT symonhamish il20activateserk12andsuppressessplicingofxboxprotein1inintestinalepithelialcellsbutdoesnotimprovepathologyinacuteorchronicmodelsofcolitis AT muelleralexandra il20activateserk12andsuppressessplicingofxboxprotein1inintestinalepithelialcellsbutdoesnotimprovepathologyinacuteorchronicmodelsofcolitis AT rahmanmarifur il20activateserk12andsuppressessplicingofxboxprotein1inintestinalepithelialcellsbutdoesnotimprovepathologyinacuteorchronicmodelsofcolitis AT hasnainsumairaz il20activateserk12andsuppressessplicingofxboxprotein1inintestinalepithelialcellsbutdoesnotimprovepathologyinacuteorchronicmodelsofcolitis |